sponsored
PatientsVille.com Logo

PatientsVille

Birth Medical Research Studies

Up-to-date List of Birth Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Birth Medical Research Studies

Rank Status Study
1 Recruiting The Midlands and North of England STILLBIRTH Study
Condition: STILLBIRTH.
Intervention: Other: Questionnaire
Outcome Measure: Identification of modifiable risk factors associated with STILLBIRTH
2 Not yet recruiting Promoting Awareness Fetal Movements to Reduce Fetal Mortality STILLBIRTH, a Stepped Wedge Cluster Randomised Trial.
Conditions: Decreased Fetal Movements Affecting Care of Mother;   Pregnancy;   STILLBIRTH
Intervention: Other: A package of interventions
Outcome Measures: Rates of STILLBIRTH;   rates of caesarean section;   Rates of induction of labour;   Rates of admission to the neonatal intensive care unit;   Proportion of women with fetal growth restriction
3 Not yet recruiting Antenatal Detection of Fetal Growth Restriction and STILLBIRTHs Rate.
Conditions: STILLBIRTH;   Intrauterine Growth Retardation;   Infant, Small for Gestational Age
Intervention: Other: Antenatal identification of fetal growth restriction
Outcome Measures: Rate of antenatal detection of FGR;   Factors associated with lack of antenatal detection of FGR in a representative sample of SGA births;   fetal deaths of SGA newborns with and without antenatal detection of FGR
4 Recruiting Using Ongoing Newborn Intervention Trials to Obtain Additional Data Critical to Maternal, Fetal and Newborn Health in a Harmonized Way
Conditions: Maternal Deaths;   Neonatal Deaths;   Still Births
Intervention: Other: This is an observational study being conducted as a substudy of antoher trial.
Outcome Measures: Burden of maternal and neonatal death and still births;   Timing of maternal and neonatal death and still births;   Causes of maternal and neonatal death and still births
5 Recruiting Comparative Evaluation of IRM and Autopsy in the Evaluation of Intra Uterine Fetal Death
Condition: Spontaneous Intra Uterine Fetal Death
Intervention: Other: Comparaison between MR and autopsy in the macroscopic evaluation of intra uterine death.
Outcome Measures: Recognition of anatomic cerebral structures evaluated by a common grid.;   Recognition and mesurement of anatomic thoracic and abdominal structures by a common grid.;   Recognition and mesurement of the placenta and umbilical cord.;   Comparaison of quality criteria of both exams.
6 Recruiting The Use of Cell Free Fetal DNA in the Maternal Blood in the Evaluation of Intrauterine Fetal Demise and Miscarriage
Conditions: Circulating Cell Free Fetal DNA;   Intrauterine Fetal Demise;   Miscarriage
Intervention:
Outcome Measures: The presence or absence of cell free fetal DNA in maternal blood in the setting of a failed pregnancy.;   The accuracy of ccffDNA compared to genetic information obtained from amniocentesis, chorionic villus sampling, fetal, or placental tissue.
7 Not yet recruiting BetterBirth: A Trial of the WHO Safe Childbirth Checklist Program
Conditions: Maternal Death;   Maternal Near Miss;   STILLBIRTH;   Neonatal Death
Intervention: Behavioral: WHO Safe Childbirth Checklist Program
Outcome Measures: Composite measure of maternal mortality, severe maternal complications, STILLBIRTHs, and neonatal mortality;   Combined maternal, fetal and newborn mortality;   Rate of maternal death;   Rate of STILLBIRTH;   Rate of severe maternal complications;   Rate of need for follow-up care for Mother;   Rate of early neonatal death;   Rate of need for follow-up care for newborn
8 Not yet recruiting A Cluster-Randomized Trial of Ultrasound Use to Improve Pregnancy Outcomes in Low Income Country Settings
Conditions: Pregnancy;   Eclampsia;   Placenta Previa;   STILLBIRTH;   Fetal Growth Restriction
Intervention: Device: Antenatal Ultrasound Scan
Outcome Measures: Composite outcome;   Rate of Women with Complicated Deliveries at Health Facilities
9 Recruiting Maternal Newborn Health Registry
Condition: Pregnancy Outcome Trends in Low-resource Geographic Areas
Intervention: Other: There is no intervention associated with this study.
Outcome Measures: Maternal mortality rate;   STILLBIRTH rate;   Early neonatal mortality rate;   Cause of maternal death at less than or equal to 42 days;   Cause of neonatal death at less than or equal to 28 days
10 Recruiting Venous Thromboembolism in Pregnancy Study
Conditions: Venous Thromboembolism;   Intrauterine Fetal Death
Intervention:
Outcome Measure:
11 Recruiting The Paediatric Virtual Autopsy Trial; Minimally Invasive, Imaging Guided Virtual Autopsy Compared to Conventional Autopsy
Conditions: STILLBIRTH;   Newborn Death;   Sudden Infant Death
Interventions: Procedure: Minimally invasive, virtual autopsy;   Procedure: Conventional autopsy
Outcome Measures: Percentage of cases for which virtual autopsy correctly identifies the cause of death and/or major pathological lesions;   Clinical indication;   MR Protocol;   Change in the ante-mortem diagnosis
12 Recruiting The Clinical and Molecular Epidemiology of Streptococcus Agalactiae Colonisation on the Kenyan Coast
Condition: Streptococcus Agalactiae (Streptococcus Group B)
Intervention:
Outcome Measures: Maternal recto-vaginal GBS colonisation;   STILLBIRTHs;   Neonatal GBS Colonisation;   Preterm birth;   Low birth weight
13 Not yet recruiting Low Dose Aspirin for the Prevention of Preeclampsia
Condition: Preeclampsia
Interventions: Drug: Aspirin;   Drug: Placebo
Outcome Measures: Prevention of preeclampsia;   Prevention of preeclampsia at term;   STILLBIRTH;   Neonatal deaths;   Neonatal intensive care unit admissions.;   Abruptio placenta;   Fetal Growth Restriction
14 Not yet recruiting Study of the Best Blastocyst Post Transfer by aCGH
Conditions: Pregnancy;   Spontaneous Abortions;   STILLBIRTH
Intervention: Procedure: Trophectoderm biopsy
Outcome Measures: Clinical pregnancy;   Trophectoderm molecular karyotype
15 Recruiting The Savella Pregnancy Registry
Condition: Fibromyalgia
Intervention:
Outcome Measures: The primary objective is to estimate the prevalence of major congenital anomalies among off-springs of women exposed to Savella during pregnancy.;   Estimate the prevalence of spontaneous abortions, STILLBIRTHs, induced abortions, minor congenital anomalies, and adverse pregnancy outcomes.
16 Recruiting EVERREST Developing a Therapy for Fetal Growth Restriction
Condition: Fetal Growth Retardation
Intervention:
Outcome Measure: data collection from pregnancies affected by severe early onset FGR.
17 Recruiting Metformin in Obese Non-diabetic Pregnant Women
Conditions: Pregnancy Complications;   Obesity
Interventions: Drug: Metformin;   Drug: Placebo
Outcome Measures: Birth Weight centile (z-score);   Maternal Weight gain;   Development of Gestational Diabetes;   Development of hypertension/Preeclampsia;   Caesarian Section;   Postpartum haemorrhage;   Neonatal Hypoglycemia;   Prematurity;   Hyperbilirubinemia;   Polycythaemia;   Respiratory Distress;   Macrosomia/Large for Gestational Age;   Birth Trauma;   Apgar score <6;   Admission to level 2 or greater neonatal unit;   STILLBIRTH/Intrauterine deaths;   2nd trimester miscarriages
18 Recruiting Evaluation of a Smartphone Application to Reduce Adverse Pregnancy Outcomes in Ethiopia
Conditions: Maternal Mortality;   Perinatal Mortality
Intervention: Other: Safe Delivery Smartphone Application
Outcome Measures: Perinatal mortality (STILLBIRTH and early neonatal death);   Postpartum haemorrhage;   Health workers clinical performance in active management of third stage of labour, postpartum haemorrhage and manual removal of placenta;   Health workers clinical performance in management of neonatal resuscitation;   Health workers knowledge of management of active management of third stage of labour, manual removal of placenta and postpartum haemorrhage;   Health workers knowledge of management of neonatal resuscitation
19 Recruiting Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants
Condition: HIV Infections
Intervention: Drug: Raltegravir
Outcome Measures: Neonatal RAL elimination (t 1/2);   RAL maternal cord blood ratio (Cohort 1 only);   Infant adverse events of Grade 3 or 4;   Adverse birth outcome: STILLBIRTH (Cohort 1 only);   Adverse birth outcome: low birth weight (Cohort 1 only);   Total bilirubin (in infant);   Direct bilirubin (in infant);   Infant death;   Optional genotyping for polymorphism of UGT1A1 from infants who are eligible for PK sampling as described in the protocol
20 Recruiting Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Populations Using Formula Feeding (PROMISE)
Condition: HIV
Interventions: Drug: Zidovudine (ZDV);   Drug: Nevirapine (NVP);   Drug: Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]);   Drug: Lamivudine-Zidovudine (3TC-ZDV);   Drug: Lopinavir-ritonavir (LPV-RTV)
Outcome Measures: Maternal Health Component: Composite endpoint of progression to AIDS-defining illness or death;   Antepartum Component: Confirmed presence of infant HIV infection;   Antepartum Component: Grade 3 or higher toxicity (for women, also selected Grade 2 hematologic, renal, and hepatic adverse events);   Antepartum Component: Obstetrical complications;   Antepartum Component: Adverse pregnancy outcomes (e.g., STILLBIRTH, preterm delivery at less than 37 weeks gestation, low birth weight less than 2,500 grams, and congenital anomalies);   Maternal Health Component: Death;   Maternal Health Component: AIDS-defining illness;   Maternal Health Component: Composite endpoint of progression to AIDS-defining illness, death, or a serious non-AIDS cardiovascular, hepatic, or renal event;   Maternal Health Component: HIV/AIDS-related events;   Maternal Health Component: Cardiovascular or other metabolic events;   Maternal Health Component: Other targeted medical conditions;   Maternal Health Component: Composite endpoint of HIV/AIDS-related event or death;   Maternal Health Component: Composite endpoint of HIV/AIDS-related event or World Health Organization (WHO) Clinical Stage 2 or 3 event;   Maternal Health Component: Composite endpoint of any condition outlined in Appendix IV of the protocol or death;   Maternal Health Component: Tuberculosis;   Maternal Health Component: Toxicity, defined as Grade 3 or greater laboratory results or signs and symptoms and selected Grade 2 renal and hepatic laboratory results;   Maternal Health Component: Viral resistance;   Maternal Health Component: Self-reported adherence;   Maternal Health Component: Quality of life;   Maternal Health Component: Changes in plasma concentrations of inflammatory and thrombogenic markers;   Maternal Health Component: Cost-effectiveness;   Antepartum Component: Infant HIV infection detected by HIV NAT positivity in the birth sample;   Antepartum Component: Overall and HIV-free infant survival;   Antepartum Component: Adherence to the maternal ARV regimen, measured by maternal report;   Antepartum Component: Cost-effectiveness and feasibility of the trial ARV regimens;   Antepartum Component: Maternal and infant viral resistance to the maternal and infant ARV strategies;   Antepartum Component: Antepartum change in HBV DNA viral load (using log HBV DNA) among women with detectable HBV DNA viral loads at baseline and other HBV outcome measures;   Antepartum Component: Maternal HIV RNA less than 400 copies/mL at delivery

These studies may lead to new treatments and are adding insight into Birth etiology and treatment.

A major focus of Birth research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Birth